CARDIOPROTECTION OF THE FUTURE: ARTIFICIAL INTELLIGENCE, GENOMICS, AND PERSONALIZED PREVENTION OF CARDIOVASCULAR DISEASES

Resumen

Cardiovascular diseases (CVD) remain the leading cause of death worldwide and continue to challenge healthcare systems despite major therapeutic advances. The rise of artificial intelligence (AI), together with progress in omics sciences—particularly predictive genomics—and the application of emerging biomarkers, is reshaping the way cardiovascular risk is identified and managed. This narrative review analyzed evidence published between 2015 and 2025 regarding the integration of machine learning algorithms, polygenic risk scores (PRS), molecular biomarkers, and continuous monitoring technologies in personalized cardiovascular prevention. The reviewed studies suggest that the convergence of AI, genomics, and biomarkers allows earlier risk detection, targeted therapy, and individualized follow-up, ushering in a new era of precision cardiovascular medicine. Nevertheless, implementation requires careful attention to ethical, regulatory, and equity aspects. It is concluded that the cardiology of the future will rely on the ability to predict, prevent, and personalize, replacing population-based models with intelligent, data-driven strategies.